Zio by iRhythm  

699 8th Street
Suite 600
San Francisco,  CA  94103

United States
https://www.irhythmtech.com

• Booth: 129

https://www.irhythmtech.com/

iRhythm Technologies is a digital health company redefining the way cardiac arrhythmias are diagnosed and managed. With over five million patients served and 1 billion hours of curated data. Zio by iRhythm is a unique cardiac monitoring service that facilitates high patient compliance and continuous ECG recording up to 14 days through simple and elegant design — enabling doctors to diagnose with certainty after a single test. Backed by over 30 clinical studies, the Zio service helps doctors confidently rule in and rule out arrhythmias, enabling more informed decision making and more precise clinical management. Zio by iRhythm reveals a clear path forward to what clinicians and patients need most — answers. For more information, please visit irhythmtech.com

 Press Releases

• Discover Zio by iRhythm at ACC.23 (Feb 03, 2023)

  There’s a better way. 

   

  The Zio service helps you accomplish your program goals by delivering superior clinical accuracy while reducing the cost of care. The service is comprised of: 

  • A single use monitor that patients prefer, with 98% patient compliance (1) 
  • The most advanced AI in cardiac monitoring (2) 
  • A curated patient report, built by Certified Cardiographic Technicians, with 99% physician agreement (3) 

   

  Healthcare providers can access patient information and interpret from their desktop or on the go via the Zio Suite portal and mobile app.  

   

   Come join us at ACC.23 in Booth #129 and speak with our team. 

  1.  Data on file. iRhythm Technologies, 2019. 

  2. Over 4 million patient records, over 1 billion hours of heart rhythm data, 34 layer deep neural network. 

   Data on file. iRhythm Technologies, 2022. 

  Hannun, AY. et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nature Medicine, 2019. 

  FDA 510K clearance.  

  Deep learned algorithm is only available in the United States. 

  3. 99% of physicians agree with the comprehensive final patient report. Based on a review of all online Zio XT and AT final patient reports. Data on file. iRhythm Technologies, 2021. 

• New groundbreaking clinical data to be presented at ACC.23 (Feb 03, 2023)

  Clinical Abstracts

   

  Saturday, March 4 | 1:30 p.m. – 1:40 p.m. 

  Jay H. Alexander, MD, Highland Park Hospital 

  Initial real world and clinical experience of the next generation ambulatory ECG Zio monitor: Implications for standard and extended wear monitoring. 

   

  Saturday, March 4 | 1:45 p.m. – 2:30 p.m. 

  Krishna Pundi, MD, Stanford University 

  Prevalence and prognostic value of ventricular tachycardia on ambulatory ECG monitoring. 

   

  Sunday, March 5 | 1:45 p.m. – 2:30 p.m. 

  Suneet Mittal, MD, Valley Medical Group 

  Comparative effectiveness of ambulatory monitors for arrhythmia diagnosis: A retrospective analysis of Medicare beneficiaries. 

   

  Monday, March 6 | 12:45 p.m. – 1:30 p.m. 

  Lohit Garg, MD, University of Pennsylvania 

  Comparison of patch versus multi-electrode cardiac monitoring for the detection of arrhythmias: The COMPARE Study. 

  * All abstracts will be presented in Hall F

 Products

 Additional Info